Postovariectomy Hypertension Is Linked to Increased Renal AT1 Receptor and Salt Sensitivity

Hypertension

Volumn 42, Issue 6, 2003, Pages 1157-1163

  Harrison Bernard, Lisa M ^a   Schulman, Ivonne Hernandez ^b   Raij, Leopoldo ^b  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Angiotensin II; Estrogen; Rats, Dahl; Rats, spontaneously hypertensive; Receptors, angiotensin; Sodium, dietary

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; CANDESARTAN; ESTRADIOL; ESTROGEN; NITRIC OXIDE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SENSITIVITY; ENDOTHELIUM; ESTROGEN THERAPY; FEMALE; HYPERTENSION; NONHUMAN; OVARIECTOMY; POSTOVARIECTOMY HYPERTENSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT STRAIN; RECEPTOR BLOCKING; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SALT INTAKE; SALT RESISTANCE; SALT SENSITIVITY; SODIUM RESTRICTION; SPONTANEOUSLY HYPERTENSIVE RAT; STRAIN DIFFERENCE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BLOOD PRESSURE; BODY WEIGHT; ESTRADIOL; ESTROGENS; FEMALE; HYPERTENSION; KIDNEY; MYOCARDIUM; ORGAN SIZE; OVARIECTOMY; RATS; RATS, INBRED DAHL; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTOR, ANGIOTENSIN, TYPE 1; SODIUM, DIETARY; TETRAZOLES;

EID: 0348109423     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000102180.13341.50     Document Type: Article

References (47)

1. Kannel WB, Wilson PW. Risk factors that attenuate the female coronary disease advantage. Arch Intern Med. 1995;155:57-61.
2. Tremollieres FA, Pouilles JM, Cauneille C, Ribot C. Coronary heart disease risk factors and menopause: a study in 1684 French women. Atherosclerosis. 1999;142:415-423.
3. Harrison-Bernard LM, Raij L. Postmenopausal hypertension. Curr Hypertens Rep. 2000;2:202-207.
4. Myers J, Morgan T. The effect of sodium intake on the blood pressure related to age and sex. Clin Exp Hypertens A. 1983;5:99-118.
5. Tominaga T, Suzuki H, Ogata Y, Shigeaki M, Saruta T. The role of sex hormones and sodium intake in postmenopausal hypertension. J Hum Hypertens. 1991;5:495-500.
6. Pechère-Bertschi A, Maillard M, Centeno C, Burnier M, Renin M. Sodium and blood pressure response to salt in women: effect of the female hormonal status. J Am Soc Nephrol. 2002;13:29A. Abstract.
7. Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. Cardiovasc Res. 2002;53:688-708.
8. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801-1811.
9. Raij L. Nitric oxide, salt sensitivity, and cardiorenal injury in hypertension. Semin Nephrol. 1999;19:296-303.
10. Campese VM. Salt sensitivity in hypertension. Renal and cardiovascular implications. Hypertension. 1994;23:531-550.
11. Weinberger MH, Fineberg NS. Sodium and volume sensitivity of blood pressure: age and pressure change over time. Hypertension. 1991;18:67-71.
12. Hayakawa H, Raij L. Nitric oxide synthase activity and renal injury in genetic hypertension. Hypertension. 1998;31:266-270.
13. Hayakawa H, Raij L. The link among nitric oxide synthase activity, endothelial function, and aortic and ventricular hypertrophy in hypertension. Hypertension. 1997;29:235-241.
14. Hayakawa H, Coffee K, Raij L. Endothelial dysfunction and cardiorenal injury in experimental salt-sensitive hypertension: effects of antihypertensive therapy. Circulation. 1997;96:2407-2413.
15. Raij L. Workshop: hypertension and cardiovascular risk factors: role of the angiotensin II-nitric oxide interaction. Hypertension. 2001;37:767-773.
16. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension. 2001;37:1199-1208.
17. Fischer M, Baessler A, Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res. 2002;53:672-677.
18. Sibonga JD, Lotinun S, Evans GL, Pribluda VS, Green SJ, Turner RT. Dose-response effects of 2-methoxyestradiol on estrogen target tissues in the ovariectomized rat. Endocrinology. 2003;144:785-792.
19. Moien-Afshari F, Kenyon E, Choy JC, Battistini B, McManus BM, Laher I. Long-term effects of ovariectomy and estrogen replacement treatment on endothelial function in mature rats. Maturitas. 2003;45:213-223.
20. Harrison-Bernard LM, El-Dahr SS, O'Leary DF, Navar LG. Regulation of angiotensin II type I receptor mRNA and protein in angiotensin II-induced hypertension. Hypertension. 1999;33[part II]:340-346.
21. 1 receptor in the adult rat kidney using a monoclonal antibody. Am J Physiol. 1997;273:F170-F177.
22. Lowry OH, Rosebrough NJ, Farr AL, Randal RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
23. 1 receptor protein expression during the early stage of diabetes mellitus. Int J Exp Diabetes Res. 2002;3:97-108.
24. 1 receptor and ACE binding in ANG II-induced hypertensive rats. Am J Physiol. 2002;282:F19-F25.
25. Otsuka K, Suzuki H, Sasaki T, Ishii N, Itoh H, Saruta T. Blunted pressure natriuresis in ovariectomized Dahl-Iwai salt-sensitive rats. Hypertension. 1996;27:119-124.
26. Fang Z, Carlson SH, Chen YF, Oparil S, Wyss JM. Estrogen depletion induces NaCl-sensitive hypertension in female spontaneously hypertensive rats. Am J Physiol-Regul Integr C. 2001;281:R1934-R1939.
27. Heimann JC, Drumond S, Alves AT, Barbato AJ, Dichtchekenian V, Marcondes M. Left ventricular hypertrophy is more marked in salt-sensitive than in salt-resistant hypertensive patients. J Cardiovasc Pharmacol. 1991;17:S122-S124.
28. Morimoto A, Uzu T, Fujii T, Nishimura M, Kuroda S, Nakamura S, Inenaga T, Kimura G. Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet. 1997;350:1734-1737.
29. Bigazzi R, Bianchi S, Baldari D, Sgherri G, Baldari G, Campese VM. Microalbuminuria in salt-sensitive patients: a marker for renal and cardiovascular risk factors. Hypertension. 1994;23:195-199.
30. Miyoshi A, Suzuki H, Fujiwara M, Masai M, Iwasaki T. Impairment of endothelial function in salt-sensitive hypertension in humans. Am J Hypertens. 1997;10:1083-1090.
31. Hinojosa-Laborde C, Lange DL, Haywood JR. Role of female sex hormones in the development and reversal of Dahl hypertension. Hypertension. 2000;35:484-489.
32. Sader MA, Celermajer DS. Endothelial function, vascular reactivity and gender differences in the cardiovascular system. Cardiovasc Res. 2002;53:597-604.
33. Dubey RK, Jackson EK. Genome and hormones: gender differences in physiology review: cardiovascular protective effects of 17B-estradiol metabolites. J Appl Physiol. 2001;91:1868-1883.
34. Szentivanyi M Jr, Zou A-P, Mattson DL, Soares P, Moreno C, Roman RJ, Cowley AW Jr. Renal medullary nitric oxide deficit of Dahl S rats enhances hypertensive actions of angiotensin II. Am J Physiol. 2002;283:R266-R272.
35. 1 receptor binding and mRNA in the female rat. Brain Res. 1999;844:34-42.
36. 1 receptor gene expression in vascular smooth muscle cells. Circulation. 2000;102:1828-1833.
37. 1 receptor gene expression in vitro and in vivo. Circulation. 1998;97:2197-2201.
38. Roesch DM, Tian Y, Zheng W, Shi M, Verbalis JG, Sandberg K. Estradiol attenuates angiotensin-induced aldosterone secretion in ovariectomized rats. Endocrinology. 2000;14:4629-4636.
39. Wassmann S, Baumer AT, Strehlow K, van Eickles M, Grohe C, Ahlbory K, Rosen R, Bohm M, Nickenig G. Endothelial dysfunction and oxidative stress during estrogen deficiency in spontaneously hypertensive rats. Circulation. 2001;103:435-441.
40. Ichiki T, Usui M, Kato M, Funakoshi Y, Ito K, Egashira K, Takeshita A. Downregulation of angiotensin II type 1 receptor gene transcription by nitric oxide. Hypertension. 1998;31:342-348.
41. Harrison DG, Galis Z, Parthasarathy S, Griendling KK. Oxidative stress and hypertension. In: Izzo, JL, Black HR, eds. Hypertension Primer. Philadelphia, Pa: Lippincott Williams & Wilkins; 1999:163-166.
42. 1 Receptor Antagonists. Philadelphia, Pa: Hanley & Belfus; 2001:189-214.
43. Malmqvist K, Kahan T, Dahl M. Angiotensin II type 1 receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. Am J Hypertens. 2000;13:504-511.
44. Fernandez-Vega F, Abellan J, Vegazo O, De Vinuesa SG, Rodriguez JC, Maceira B, De Castro SS, Nicolas RR, Luno J. Angiotensin II type 1 receptor blockade to control blood pressure in postmenopausal women: influence of hormone replacement therapy. Kidney Int. 2002;62(suppl 82):36-41.
45. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288:49-57.
46. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
47. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, Furberg CD, Kowalchuk GJ, Stuckey TD, Rogers WJ, Givens DH, Waters D. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000;343:522-529.